Atea Pharmaceuticals, Inc. (AVIR) stock
AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.96−0.16 (-3.88%)
Close on Nov 17, 2026Market cap $317.61MP/E –Yield –
Atea Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Atea Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $155.45M, up 36.7% year over year. For fiscal 2025 it was $148.02M, up 2.7% from the year before. The highest annual figure on record is $167.21M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $148.02M | +2.7% |
| FY2024 | Dec 31, 2024 | $144.10M | +26.1% |
| FY2023 | Dec 31, 2023 | $114.24M | +39.4% |
| FY2022 | Dec 31, 2022 | $81.94M | -51.0% |
| FY2021 | Dec 31, 2021 | $167.21M | +339.7% |
| FY2020 | Dec 31, 2020 | $38.02M | +273.9% |
| FY2019 | Dec 31, 2019 | $10.17M | +52.4% |
| FY2018 | Dec 31, 2018 | $6.68M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $28.15M | -12.8% |
| Q1 FY2026 | Mar 31, 2026 | $41.13M | +39.0% |
| Q4 FY2025 | Dec 31, 2025 | $47.82M | +86.3% |
| Q3 FY2025 | Sep 30, 2025 | $38.35M | +46.6% |
| Q2 FY2025 | Jun 30, 2025 | $32.28M | -7.0% |
| Q1 FY2025 | Mar 31, 2025 | $29.58M | -48.6% |
| Q4 FY2024 | Dec 31, 2024 | $25.67M | -26.7% |
| Q3 FY2024 | Sep 30, 2024 | $26.16M | -7.2% |
| Q2 FY2024 | Jun 30, 2024 | $34.70M | +57.3% |
| Q1 FY2024 | Mar 31, 2024 | $57.58M | +98.8% |
| Q4 FY2023 | Dec 31, 2023 | $35.05M | +27.3% |
| Q3 FY2023 | Sep 30, 2023 | $28.18M | +474.5% |
| Q2 FY2023 | Jun 30, 2023 | $22.06M | +11.1% |
| Q1 FY2023 | Mar 31, 2023 | $28.95M | -2.3% |
| Q4 FY2022 | Dec 31, 2022 | $27.54M | -52.4% |
| Q3 FY2022 | Sep 30, 2022 | $4.91M | -88.6% |
| Q2 FY2022 | Jun 30, 2022 | $19.86M | -50.1% |
| Q1 FY2022 | Mar 31, 2022 | $29.63M | +11.5% |
| Q4 FY2021 | Dec 31, 2021 | $57.81M | +317.5% |
| Q3 FY2021 | Sep 30, 2021 | $43.02M | +216.3% |
| Q2 FY2021 | Jun 30, 2021 | $39.80M | +413.3% |
| Q1 FY2021 | Mar 31, 2021 | $26.57M | +841.9% |
| Q4 FY2020 | Dec 31, 2020 | $13.85M | +296.8% |
| Q3 FY2020 | Sep 30, 2020 | $13.60M | +464.1% |
| Q2 FY2020 | Jun 30, 2020 | $7.76M | – |
| Q1 FY2020 | Mar 31, 2020 | $2.82M | – |
| Q4 FY2019 | Dec 31, 2019 | $3.49M | – |
| Q3 FY2019 | Sep 30, 2019 | $2.41M | – |
See a number that looks wrong?